Zhong Guo Jing Ji Wang·2025-07-13 08:29Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. plans to raise up to 3.764 billion yuan through a private placement of A-shares, with proceeds earmarked for innovative drug research and development [2][4]. Group 1: Issuance Details - The company intends to issue shares to no more than 35 specific investors, including various financial institutions and qualified investors as defined by the China Securities Regulatory Commission (CSRC) [3]. - The issuance price will be no less than 80% of the average trading price of the company's shares over the 20 trading days prior to the pricing date [3]. - The total number of shares issued will not exceed 5% of the company's total share capital prior to the issuance, amounting to a maximum of 20,050,000 shares [4]. Group 2: Control and Ownership - The controlling shareholder, Zhu Yi, holds 29,815,940 shares, representing 74.35% of the total share capital before the issuance, and will maintain control post-issuance [4]. - After the issuance, Zhu Yi's ownership will decrease to 70.81% based on the maximum issuance scenario, ensuring that control of the company remains unchanged [4]. Group 3: Underwriting and Representation - The lead underwriter for this issuance is CITIC Securities Co., Ltd., with Yang Qin and Chen Wen serving as the sponsoring representatives [5].